Brand Intelligence Graph
Company Overview
About Microbiotica
Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.
Business Model & Competitive Advantage
Spun out of the Wellcome Sanger Institute in 2017, Microbiotica has demonstrated that specific microbiome compositions predict and mediate response to cancer immunotherapy (checkpoint inhibitors). Its lead programs aim to convert non-responders into responders by supplementing their microbiome with beneficial bacterial strains. Phase 1/2 trials in combination with anti-PD1 therapies are underway.
Competitive Landscape 2025–2026
The $105M Series C in 2025 will fund clinical advancement of Microbiotica's oncology and inflammatory bowel disease (IBD) programs. As the microbiome field matures from correlation to causation, Microbiotica's database advantage and clinical momentum position it as a leader in what could become a multi-billion dollar therapeutic category.
Key Differentiators
Emerging Innovator
Microbiotica is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Finch Therapeutics
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Microbiotica with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Microbiotica? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Microbiotica Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Microbiotica vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →